Cargando…
Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market
BACKGROUND: Pharmaceutical industry is knowledge-intensive and highly globalized, in both developed and developing countries. On the other hand, if companies want to survive, they should be able to compete well in both domestic and international markets. The main purpose of this paper is therefore t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234990/ https://www.ncbi.nlm.nih.gov/pubmed/24708770 http://dx.doi.org/10.1186/2008-2231-22-35 |
_version_ | 1782344945115332608 |
---|---|
author | Shabaninejad, Hosein Mehralian, Gholamhossein Rashidian, Arash Baratimarnani, Ahmad Rasekh, Hamid Reza |
author_facet | Shabaninejad, Hosein Mehralian, Gholamhossein Rashidian, Arash Baratimarnani, Ahmad Rasekh, Hamid Reza |
author_sort | Shabaninejad, Hosein |
collection | PubMed |
description | BACKGROUND: Pharmaceutical industry is knowledge-intensive and highly globalized, in both developed and developing countries. On the other hand, if companies want to survive, they should be able to compete well in both domestic and international markets. The main purpose of this paper is therefore to develop and prioritize key factors affecting companies’ competitiveness in pharmaceutical industry. Based on an extensive literature review, a valid and reliable questionnaire was designed, which was later filled up by participants from the industry. To prioritize the key factors, we used the Technique for Order Preference by Similarity to Ideal Solution (TOPSIS). RESULTS: The results revealed that human capital and macro-level policies were two key factors placed at the highest rank in respect of their effects on the competitiveness considering the industry-level in pharmaceutical area. CONCLUSION: This study provides fundamental evidence for policymakers and managers in pharma context to enable them formulating better polices to be proactively competitive and responsive to the markets’ needs. |
format | Online Article Text |
id | pubmed-4234990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42349902014-11-19 Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market Shabaninejad, Hosein Mehralian, Gholamhossein Rashidian, Arash Baratimarnani, Ahmad Rasekh, Hamid Reza Daru Research Article BACKGROUND: Pharmaceutical industry is knowledge-intensive and highly globalized, in both developed and developing countries. On the other hand, if companies want to survive, they should be able to compete well in both domestic and international markets. The main purpose of this paper is therefore to develop and prioritize key factors affecting companies’ competitiveness in pharmaceutical industry. Based on an extensive literature review, a valid and reliable questionnaire was designed, which was later filled up by participants from the industry. To prioritize the key factors, we used the Technique for Order Preference by Similarity to Ideal Solution (TOPSIS). RESULTS: The results revealed that human capital and macro-level policies were two key factors placed at the highest rank in respect of their effects on the competitiveness considering the industry-level in pharmaceutical area. CONCLUSION: This study provides fundamental evidence for policymakers and managers in pharma context to enable them formulating better polices to be proactively competitive and responsive to the markets’ needs. BioMed Central 2014-04-03 /pmc/articles/PMC4234990/ /pubmed/24708770 http://dx.doi.org/10.1186/2008-2231-22-35 Text en Copyright © 2014 Shabaninejad et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Shabaninejad, Hosein Mehralian, Gholamhossein Rashidian, Arash Baratimarnani, Ahmad Rasekh, Hamid Reza Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market |
title | Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market |
title_full | Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market |
title_fullStr | Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market |
title_full_unstemmed | Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market |
title_short | Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market |
title_sort | identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234990/ https://www.ncbi.nlm.nih.gov/pubmed/24708770 http://dx.doi.org/10.1186/2008-2231-22-35 |
work_keys_str_mv | AT shabaninejadhosein identifyingandprioritizingindustrylevelcompetitivenessfactorsevidencefrompharmaceuticalmarket AT mehraliangholamhossein identifyingandprioritizingindustrylevelcompetitivenessfactorsevidencefrompharmaceuticalmarket AT rashidianarash identifyingandprioritizingindustrylevelcompetitivenessfactorsevidencefrompharmaceuticalmarket AT baratimarnaniahmad identifyingandprioritizingindustrylevelcompetitivenessfactorsevidencefrompharmaceuticalmarket AT rasekhhamidreza identifyingandprioritizingindustrylevelcompetitivenessfactorsevidencefrompharmaceuticalmarket |